Treatment of inflammatory myopathy: emerging therapies and therapeutic targets

References

• Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65(2):314-24
   PubMed Web of Science ®Google Scholar
• Bunch TW, Worthington JW, Combs JJ, et al. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 1980;92(3):365-9
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329(27):1993-2000
   PubMed Web of Science ®Google Scholar
• Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992;326(21):1380-4
   PubMed Web of Science ®Google Scholar
• Troyanov Y, Targoff IN, Tremblay JL, et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005;84(4):231-49
   PubMed Web of Science ®Google Scholar
• Koenig M, Fritzler MJ, Targoff IN, et al. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007;9(4):R78
   PubMed Web of Science ®Google Scholar
• Rider LG, Werth VP, Huber AM, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient/parent global activity, manual muscle testing (MMT), health assessment questionnaire (HAQ)/childhood health assessment questionnaire (C-HAQ), childhood myositis assessment scale (CMAS), myositis disease activity assessment tool (MDAAT), disease activity score (DAS), short form 36 (SF-36), child health questionnaire (CHQ), physician global damage, myositis damage index (MDI), quantitative muscle testing (QMT), myositis functional index-2 (FI-2), myositis activities profile (MAP), inclusion body myositis functional rating scale (IBMFRS), cutaneous dermatomyositis disease area and severity index (CDASI), cutaneous assessment tool (CAT), dermatomyositis skin severity index (DSSI), skindex, and dermatology life quality index (DLQI). Arthritis Care Res (Hoboken) 2011;63(Suppl 11):S118-57
   PubMed Web of Science ®Google Scholar
• Oddis CV, Rider LG, Reed AM, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005;52(9):2607-15
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Allen E, Farewell V, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004;43(1):49-54
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Rider LG, Ruperto N, et al. A consensus hybrid definition using a conjoint analysis is proposed as response criteria for minimal and moderate improvement in adult polymyositis and dermatomyositis clinical trials. Arthritis and Rheum 2014;64:10 Suppl
   Google Scholar
• Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993;94(4):379-87
   PubMed Web of Science ®Google Scholar
• Bolosiu HD, Man L, Rednic S. The effect of methylprednisolone pulse therapy in polymyositis/dermatomyositis. Adv Exp Med Biol 1999;455:349-57
   PubMed Web of Science ®Google Scholar
• Combined treatment of methotrexate + glucocorticoids versus glucocorticoids alone in patients with polymyositis and dermatomyositis (Prometheus). Available from: https://clinicaltrials.gov/ct2/show/NCT00651040
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00651040?term=methotrexate+myositis&rank=1
   Google Scholar
• Newman ED, Scott DW. The use of low-dose oral methotrexate in the treatment of polymyositis and dermatomyositis. J Clin Rheumatol 1995;1(2):99-102
   PubMedGoogle Scholar
• Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004;43(2):143-7
   PubMed Web of Science ®Google Scholar
• Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 1981;24(1):45-8
   PubMed Web of Science ®Google Scholar
• Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002;47:614-22
   PubMed Web of Science ®Google Scholar
• Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001;164:1182-5
   PubMed Web of Science ®Google Scholar
• Miller J, Walsh Y, Saminaden S, et al. Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci 2002;199(Suppl 01):S53
   Google Scholar
• Schiopu E, Phillips K, MacDonald PM, et al. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther 2012;14(1):R22
   PubMed Web of Science ®Google Scholar
• Yu KH, Wu YJ, Kuo CF, et al. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol 2011;30(12):1595-601
   PubMed Web of Science ®Google Scholar
• Villalba L, Hicks JE, Adams EM, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998;41(3):392-9
   PubMed Web of Science ®Google Scholar
• Pisoni CN, Cuadrado MJ, Khamashta MA, et al. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford) 2007;46(3):516-18
   PubMed Web of Science ®Google Scholar
• Rowin J, Amato AA, Deisher N, et al. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 2006;66(8):1245-7
   PubMed Web of Science ®Google Scholar
• Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005;44(3):386-9
   PubMed Web of Science ®Google Scholar
• Schneider C, Gold R, Schäfers M, Toyka KV. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 2002;25(2):286-8
   PubMed Web of Science ®Google Scholar
• Danieli MG, Calcabrini L, Calabrese V, et al. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev 2009;9(2):124-7
   PubMed Web of Science ®Google Scholar
• Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006;142(1):65-9
   PubMed Web of Science ®Google Scholar
• Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 2000;27(6):1542-5
   PubMed Web of Science ®Google Scholar
• Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci 2009;337(5):329-35
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006;130(1):30-6
   PubMed Web of Science ®Google Scholar
• Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken) 2010;62(10):1496-501
   PubMed Web of Science ®Google Scholar
• Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013;40(5):640-6
   PubMed Web of Science ®Google Scholar
• Yamadori I, Fujita J, Kajitani H, et al. Lymphocyte subsets in lung tissues of interstitial pneumonia associated with untreated polymyositis/dermatomyositis. Rheumatol Int 2001;21:89-93
   PubMed Web of Science ®Google Scholar
• Katagiri A, Morimoto S, Nakiri Y, et al. Decrease in CD4+CD25+ and CD8+CD28+ T cells in interstitial pneumonitis associated with rheumatic disease. Mod Rheumatol 2008;18:562-9
   PubMed Web of Science ®Google Scholar
• Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005;38:383-92
   PubMed Web of Science ®Google Scholar
• Kotani T, Makino S, Takeuchi T, et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol 2008;35:254-9
   PubMed Web of Science ®Google Scholar
• Kotani T, Takeuchi T, Makino S, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol 2011;30:1021-8
   PubMed Web of Science ®Google Scholar
• Ingegnoli F, Lubatti C, Ingegnoli A, et al. Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. Autoimmun Rev 2012;11:335-40
   PubMed Web of Science ®Google Scholar
• Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol 2000;27:2855-9
   PubMed Web of Science ®Google Scholar
• Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999;353:1762-3
   PubMed Web of Science ®Google Scholar
• Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005;52:2439-46
   PubMed Web of Science ®Google Scholar
• Mitsui T, Kuroda Y, Ueno S, Kaji R. The effects of FK506 on refractory inflammatory myopathies. Acta Neurol Belg 2011;111(3):188-94
   PubMed Web of Science ®Google Scholar
• Ochi S, Nanki T, Takada K, et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol 2005;23:707-10
   PubMed Web of Science ®Google Scholar
• Labirua-Iturburu A, Selva-O’Callaghan A, Martínez-Gómez X, et al. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol 2013;31:436-9
   PubMed Web of Science ®Google Scholar
• Cronin ME, Miller FW, Hicks JE, et al. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 1989;16(9):1225-8
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007;46:124-30
   PubMed Web of Science ®Google Scholar
• Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005;32:1719-26
   PubMed Web of Science ®Google Scholar
• Mok CC, To CH, Szeto ML. Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. Scand J Rheumatol 2003;32:181-3
   PubMed Web of Science ®Google Scholar
• Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002;46(2):467-74
   PubMed Web of Science ®Google Scholar
• Danieli MG, Pettinari L, Moretti R, et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011;10(3):144-9
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 2009;187:201-6
   PubMed Web of Science ®Google Scholar
• Bakewell CJ, Raghu G. Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest 2011;139:441-3
   PubMed Web of Science ®Google Scholar
• Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012;78(13):1009-15
   PubMed Web of Science ®Google Scholar
• Mahler EA, Blom M, Voermans NC, et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) 2011;50(12):2206-13
   PubMed Web of Science ®Google Scholar
• Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010;62(9):1328-34
   PubMed Web of Science ®Google Scholar
• Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006;65(7):974-5
   PubMed Web of Science ®Google Scholar
• Lambotte O, Kotb R, Maigne G, et al. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005;32(7):1369-70
   PubMed Web of Science ®Google Scholar
• Arlet JB, Dimitri D, Pagnoux C, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 2006;16(5):334-6
   PubMed Web of Science ®Google Scholar
• Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52(2):601-7
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 2007;34(9):1864-8
   PubMed Web of Science ®Google Scholar
• Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007;143(6):763-7
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014;66(3):740-9
   PubMed Web of Science ®Google Scholar
• Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014;19:353-9
   PubMed Web of Science ®Google Scholar
• Andersson H, Sem M, Lund MB, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford) 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Iannone F, Scioscia C, Falappone PC, et al. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006;33(9):1802-4
   PubMed Web of Science ®Google Scholar
• Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011;70(3):427-36
   PubMed Web of Science ®Google Scholar
• Hengstman GJ, van den Hoogen FH, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003;50(1):10-15
   PubMed Web of Science ®Google Scholar
• Selva-O’Callaghan A, Martínez-Costa X, Solans-Laque R, et al. Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology (Oxford) 2004;43(9):1196-7
   PubMed Web of Science ®Google Scholar
• Anandacoomarasamy A, Howe G, Manolios N. Advanced refractory polymyositis responding to infliximab. Rheumatology (Oxford) 2005;44(4):562-3
   PubMed Web of Science ®Google Scholar
• Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol 2004;52(1):61-3
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006;65(9):1233-6
   PubMed Web of Science ®Google Scholar
• Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67(12):1670-7
   PubMed Web of Science ®Google Scholar
• Coyle K, Pokrovnichka A, French K. A randomized double blind placebo controlled trial of infliximab in patients with polymyositis and dermatomyositis. Arthritis Res 2008;58:S293
   Google Scholar
• Hengstman GJ, De Bleecker JL, Feist E. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 2008;59(3-4):159-63
   PubMed Web of Science ®Google Scholar
• Riolo G, Towheed TE. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. J Rheumatol 2012;39(1):192-4
   PubMed Web of Science ®Google Scholar
• Klein R, Rosenbach M, Kim EJ, et al. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 2010;146(7):780-4
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Yukawa N, Ohmura K, et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol 2010;29(5):563-6
   PubMed Web of Science ®Google Scholar
• Brunasso AM, Scocco GL, Massone C. Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol 2010;37(7):1549-50
   PubMed Web of Science ®Google Scholar
• Catania A, Lonati C, Sordi A, et al. The melanocortin system in control of inflammation. ScientificWorldJournal 2010;10:1840-53
   PubMed Web of Science ®Google Scholar
• Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Devel Ther 2012;6:133-9
   PubMed Web of Science ®Google Scholar
• Acthar in treatment of refractory dermatomyositis and polymyositis. Available from: https://clinicaltrials.gov/ct2/show/NCT01906372
   Google Scholar
• Lepidi H, Frances V, Figarella-Branger D, et al. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 1998;24(1):73-9
   PubMed Web of Science ®Google Scholar
• Gabay C, Gay-Croisier F, Roux-Lombard P, et al. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 1994;37(12):1744-51
   PubMed Web of Science ®Google Scholar
• Lundberg I, Ulfgren AK, Nyberg P, et al. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40(5):865-74
   PubMed Web of Science ®Google Scholar
• Narazaki M, Hagihara K, Shima Y. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 2011;50(7):1344-6
   PubMed Web of Science ®Google Scholar
• Kondo M, Murakawa Y, Matsumura T, et al. A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatology (Oxford) 2014;53(10):1907-8
   PubMed Web of Science ®Google Scholar
• Tocilizumab in the treatment of refractory polymyositis and dermatomyositis (TIM). Available from: https://clinicaltrials.gov/ct2/show/NCT02043548
   Google Scholar
• Murata K, Dalakas MC. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 1999;155(2):453-60
   PubMed Web of Science ®Google Scholar
• Nagaraju K, Raben N, Villalba ML, et al. Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol 1999;92(2):161-9
   PubMed Web of Science ®Google Scholar
• Musuruana JL, Cavallasca JA. Abatacept for treatment of refractory polymyositis. Joint Bone Spine 2011;78(4):431-2
   PubMed Web of Science ®Google Scholar
• Arabshahi B, Silverman RA, Jones OY, Rider LG. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 2012;160(3):520-2
   PubMed Web of Science ®Google Scholar
• Maeshima K, Kiyonaga Y, Imada C, et al. Successful treatment of refractory anti-signal recognition particle myopathy using abatacept. Rheumatology (Oxford) 2014;53(2):379-80
   PubMed Web of Science ®Google Scholar
• Kerola AM, Kauppi MJ. Abatacept as a successful therapy for myositis—a case-based review. Clin Rheumatol 2015;34(3):609-12
   PubMed Web of Science ®Google Scholar
• Thompson B, Corris P, Miller JA, et al. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol 2008;35(10):2080-2
   PubMed Web of Science ®Google Scholar
• Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57(5):664-78
   PubMed Web of Science ®Google Scholar
• Walsh RJ, Kong SW, Yao Y, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007;56(11):3784-92
   PubMed Web of Science ®Google Scholar
• Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007;13(1-2):59-68
   PubMed Web of Science ®Google Scholar
• Bilgic H, Ytterberg SR, Amin S, et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009;60(11):3436-46
   PubMed Web of Science ®Google Scholar
• Higgs BW, Zhu W, Morehouse C, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2014;73(1):256-62
   PubMed Web of Science ®Google Scholar